Table 2.
Results of the main trials evaluating anti-PD1/PD-L1 monotherapy in stage IV NSCLC.
| Histology | PDL1 | n | ORR (%) * | OS (mo) * | Ref. | |
|---|---|---|---|---|---|---|
| First-line | ||||||
| Nivolumab | NSCLC | >5% | 271 | 26 vs. 33 | 13.7 vs. 13.8 | [54] |
| Pembrolizumab | NSCLC | >50% | 154 | 45 vs. 28 | 30 vs. 14.2 | [55] |
| NSCLC | >1% | 638 | 27 vs. 27 | 16.7 vs. 12.1 | [56] | |
| Atezolizumab | NSCLC | >1% | 277 | 38.3 vs. 28.6 | 20.2 vs. 13.1 | [57] |
| Durvalumab | NSCLC | >25% | 369 | 35.6 vs. 37.7 | 16.3 vs. 12.9 | [58] |
| Cemiplimab | NSCLC | >50% | 283 | 37 vs. 21 | 22.1 [17.5-NR] vs. 14.2 | [59] |
| Second- or third-line | ||||||
| Nivolumab | Squamous | All | 135 | 20 vs. 9 | 9.2 vs. 6 | [60] |
| Adenocarcinoma | All | 292 | 19 vs. 12 | 12.2 vs. 9.4 | [61] | |
| Pembrolizumab | NSCLC | >1% | 344 | 18 vs. 9.3 | 10.4 vs. 8.5 | [62] |
| Atezolizumab | NSCLC | All | 425 | 14 vs. 13 | 13.8 vs. 9.6 | [63] |
n: number of patients in the experimental arm. ORR: objective response rate. OS: overall survival. * comparison of ORR and OS data is given in the following format: experimental arm (anti-PD1/PD-L1) versus standard of care arm (chemotherapy).